Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis

Matsuda, Kazunobu; Miyoshi, Hiroaki; Hiraoka, Koji; Hamada, Tetsuya; Shiro, Yoshitsugu; Ishibashi, Yukinao; Haraguchi, Toshiaki; Shiba, Naoto; Ohshima, Koichi

doi:10.1007/s10238-018-0515-4

Cited by 19 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The engagement of Tregs with autoreactive B cells via the PD-1/L1 inhibitory axis can trigger B cells apoptosis and inhibit the production of autoantibody ( 22 ). In patients with RA, lymphocytes infiltrating the synovium commonly express PD-1, the synovial lining cells express PD-L1, and the number of PD-1-positive lymphocytes was significantly larger in RA than in osteoarthritis ( 23 ). In addition, the PD-L1 expression on synovial lining cells was positively related to the number of infiltrating T cells and Krenn’s synovitis score ( 23 ), indicating an important role of PD-1 pathway in RA.…”

Section: Relationship Between Immune Checkpoints and Aidmentioning

confidence: 99%

“…In patients with RA, lymphocytes infiltrating the synovium commonly express PD-1, the synovial lining cells express PD-L1, and the number of PD-1-positive lymphocytes was significantly larger in RA than in osteoarthritis ( 23 ). In addition, the PD-L1 expression on synovial lining cells was positively related to the number of infiltrating T cells and Krenn’s synovitis score ( 23 ), indicating an important role of PD-1 pathway in RA. Notably, in non-obese diabetic mice, both anti–CTLA-4 and anti–PD-1 treatment can prevent anergy induction in islet antigen–specific T cells, but only PD-1/L1 blockade can reverse experimentally induced anergy, indicating a unique function for PD-1 signaling in maintaining T cells anergy ( 24 ).…”

Section: Relationship Between Immune Checkpoints and Aidmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

2021

View full text Add to dashboard Cite

Immune checkpoint inhibitor (ICI) is a revolutionary breakthrough in the field of cancer treatment. Because of dysregulated activation of the immune system, patients with autoimmune disease (AID) are usually excluded from ICI clinical trials. Due to a large number of cancer patients with preexisting AID, the safety and efficacy of ICIs in these patients deserve more attention. This review summarizes and analyzes the data regarding ICI therapy in cancer patients with preexisting AID from 17 published studies. Available data suggests that the efficacy of ICIs in AID patients is comparable to that in the general population, and the incidence of immune-related adverse events (irAEs) is higher but still manageable. It is recommended to administer ICIs with close monitoring of irAEs in patients with a possibly high benefit-risk ratio after a multidisciplinary discussion based on the patient’s AID category and severity, the patient’s tumor type and prognosis, alternative treatment options, and the patient’s intention. Besides, the prevention and management of irAEs in AID patients have been discussed.

show abstract

Section: Relationship Between Immune Checkpoints and Aidmentioning

confidence: 99%

Section: Relationship Between Immune Checkpoints and Aidmentioning

confidence: 99%

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

2021

View full text Add to dashboard Cite

show abstract

“…In patients with chronic RA, the plasma level of sPD-1 was also significantly higher than in healthy volunteers [37]. Studies observed that the expression of sPD-1/ sPD-L1 increased in serum of RA patients, and the expression of mPD-1/mPD-L1 also increased in synovial tissue and spleen [38,39]. CD4+T cells were cocultured with synovial fluid mononuclear cells in vitro, and the addition of high concentration of sPD-L1 fusion protein could promote the proliferation of T cells [4].…”

Section: Discussionmentioning

confidence: 99%

The Effects of Moxibustion on PD-1/PD-L1-Related Molecular Expression and Inflammatory Cytokine Levels in RA Rats

Zhong

Lai

Zhang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. Rheumatoid arthritis (RA) is an autoimmune disease that starts with inflammation of the synovium. The pain and joint dysfunction caused by RA urgently need an effective treatment to alleviate the inflammatory reaction and delay the progression of the disease. The pathological damage of RA is proposed to associate with the dysfunction of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway. Moxibustion, as a main complementary therapy of traditional Chinese medicine (TCM), has been proved effective to reduce chronic inflammatory reaction on RA, but whether the anti-inflammatory effects are mediated by PD-1/PD-L1 pathway is still unclear. Therefore, moxibustion was conducted in the rats with RA to investigate its effect on PD-1/PD-L1. Methods. The rats' right hind paws were injected with Freundʼs complete adjuvant (FCA) to establish the model of RA. Seven days after the injection of FCA, moxibustion therapy was performed on the acupoints of Shenshu (BL23) and Zusanli (ST36) once a day for three weeks. Then, ELISA and immunohistochemical methods were used to analyze the influence of moxibustion on the expression of PD-1/PD-L1. If the moxibustion had an effect on the expression of PD-1/PD-L1-related molecules, we would knock down PD-1 with adenovirus vector. After moxibustion therapy, ELISA and histological analysis were performed to observe the anti-inflammatory effect of moxibustion. Results. The results demonstrated that moxibustion had an effect on the expression of PD-1-related molecules. The results of ELISA manifested that moxibustion decreased the level of IFN-γ and increased the level of IL-4 and IL-10. HE staining revealed that moxibustion alleviated the proliferation of synovial tissue. However, the anti-inflammatory effect and pathological improvement were weakened when PD-1 was blocked. Conclusions. The results indicate that moxibustion affected the expression of PD-1/PD-L1-related molecules and can effectively treat RA damage. The anti-inflammatory effect of moxibustion was weakened when PD-1 was knocked down.

show abstract

“…A number of RA studies have reported PD-1 expression on T cells infiltrating the synovial membrane, synovial fluid, and peripheral blood, as well as the PD-L1 expression on the synovial tissue and synovial fluid [ 108 , 109 , 110 ]. Higher PD-L1 expression on the synovial lining cells was associated with an RF positive state, more infiltrating CD3-positive T cells, higher CRP, and more pronounced synovitis in RA [ 109 ].…”

Section: Immune Checkpoints Are Promising Targets For Targeted Immuno...mentioning

confidence: 99%

Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases

Gerasimova

Tabakov

Gerasimova

et al. 2022

IJMS

View full text Add to dashboard Cite

In addition to identifying the major B- and T-cell subpopulations involved in autoimmune rheumatic diseases (ARDs), in recent years special attention has been paid to studying the expression of their activation markers and immune checkpoints (ICPs). The activation markers on B and T cells are a consequence of the immune response, and these molecules are considered as sensitive specific markers of ARD activity and as promising targets for immunotherapy. ICPs regulate the activation of the immune response by preventing the initiation of autoimmune processes, and they modulate it by reducing immune cell-induced organ and tissue damage. The article considers the possible correlation of ICPs with the activity of ARDs, the efficacy of specific ARD treatments, and the prospects for the use of activation molecules and activation/blocking ICPs for the treatment of ARDs.

show abstract

Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis

Cited by 19 publications

References 30 publications

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

The Effects of Moxibustion on PD-1/PD-L1-Related Molecular Expression and Inflammatory Cytokine Levels in RA Rats

Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases

Contact Info

Product

Resources

About